Lunit Inc. (KOSDAQ:328130)

South Korea flag South Korea · Delayed Price · Currency is KRW
44,100
-2,000 (-4.34%)
Nov 7, 2025, 3:30 PM KST
-4.34%
Market Cap1.29T
Revenue (ttm)73.89B
Net Income (ttm)-118.14B
Shares Out29.20M
EPS (ttm)-4,077.58
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume620,299
Average Volume329,895
Open46,800
Previous Close46,100
Day's Range43,500 - 46,850
52-Week Range35,900 - 85,800
Beta1.32
RSI57.72
Earnings DateNov 13, 2025

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a... [Read more]

Sector Technology
Founded 2013
Employees 298
Stock Exchange KOSDAQ
Ticker Symbol 328130
Full Company Profile

Financial Performance

In 2024, Lunit's revenue was 54.18 billion, an increase of 116.03% compared to the previous year's 25.08 billion. Losses were -82.42 billion, 124.0% more than in 2023.

Financial Statements

News

There is no news available yet.